Search clinical trials for: recurrent ovarian epithelial cancer

Total 97416 results

Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (MITO27)

Ovarian Cancer

Italy
National University Hospital, Singapore

Unknown

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Ovarian Clear Cell Carcinoma

Singapore
Yonsei University

Completed

The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial

Ovarian Cancer (Epithelial)

Korea, Republic of
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Epithelial Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
PharmaMar, Spain

Completed

An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer (NIS-OvaYond)

Recurrent Ovarian Cancer

Germany
National Cancer Institute (NCI)

Completed

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage... and other conditions

United States
Accenture

Completed

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

Australia, Russian Federation, United Kingdom
Suriya Yessentayeva
Johnson & Johnson

Unknown

An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer (Renaissance)

Ovarian Cancer

Kazakhstan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
Oncolix, Inc.

Unknown

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Ovarian Cancer | Peritoneal Cavity Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Corcept Therapeutics

Completed

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Sarcoma | Breast Cancer | Prostatic Neoplasms | Carcinoma, Transitional Cell | Prostate Cancer | Non-small Cell Lung Cancer | Ovarian Epithelial Cancer Recurrent

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Terminated

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Endometrioid Tumor | Malignant Ovarian Serous Tumor

United States
Masonic Cancer Center, University of Minnesota

Completed

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

Ovarian Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota
Celgene Corporation

Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
Masonic Cancer Center, University of Minnesota
Incyte Corporation

Completed

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
Masonic Cancer Center, University of Minnesota

Terminated

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Sarcoma | Kidney Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Chordoma | Neuroblastoma | Retinoblastoma | Liver Cancer | Childhood Germ Cell Tumor

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer
National Cancer Institute (NCI)

Completed

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Adult Solid Neoplasm

United States, Canada
University of Texas Southwestern Medical Center
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Yang Zhijun

Unknown

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Ovarian Cancer | Endometrial Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
EMD Serono

Withdrawn

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Ovarian Cancer
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI)

Completed

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
George Washington University

Withdrawn

Toremifene in Treating Patients With Ovarian Cancer

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
GlaxoSmithKline

Completed

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Neoplasms, Ovarian

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer

Breast Cancer | Fatigue | Ovarian Cancer | Psychosocial Effects of Cancer and Its Treatment

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada

Search clinical trials for: recurrent ovarian epithelial cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations